China approves Daklinza/Sunvepra combo for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir (BMS-790052) in combination with Sunvepra asunaprevir to treat HCV genotype 1b infection in patients with or without cirrhosis. The company said it is CFDA's first approval of an all-oral, interferon- and ribavirin-free HCV regimen. BMS markets both Daklinza and Sunvepra.

CFDA also approved Daklinza in combination with other agents, including Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), for adults with genotype 1-6 infection. Sovaldi is under CFDA review, but is not yet approved in the country...